Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Acurx Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Acurx Pharmaceuticals, Inc.

ACXP

Acurx Pharmaceuticals, Inc.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals develops novel small molecule antibiotics targeting Gram-positive bacterial infections, focusing on DNA polymerase IIIC inhibition. Its lead candidate, ibezapolstat, addresses Clostridioides difficile infections with a unique mechanism that preserves beneficial gut microbiota and reduces recurrence. The company’s pipeline also targets resistant pathogens like MRSA and VRE. Acurx operates in the antimicrobial resistance sector, aiming to provide safer, effective treatments for serious bacterial infections through clinical-stage drug development.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Acurx Pharmaceuticals, Inc.

1
1
Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals Reports Q1 2026 Financial Results with $1.68 Million Net Loss

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals Reports $7.97 Million Net Loss, Advances Ibezapolstat Clinical Trials

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals Reports $1.99 Million Net Loss in Q3 2025, Down 29% Year-Over-Year

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals Reports Significant Reduction in Operating Expenses and Net Losses for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals Reports 51% Reduction in Financial Losses for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals Reports Financial Results, Raises Funds Amid Ongoing Clinical Development of Ibezapolstat

Via official filing (AI summary) | over 1 year ago | 0 comments